Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / SBFM - The Buzz Show: Sunshine Biopharma (SBFM: NASDAQ) Agreement with a LNP Formulation Company


SBFM - The Buzz Show: Sunshine Biopharma (SBFM: NASDAQ) Agreement with a LNP Formulation Company

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company”

Sunshine Biopharma Inc. (NASDAQ: SBFM) , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle (“LNP”) companies. The purpose of the collaboration is to advance the development of Sunshine Biopharma’s mRNA-based anticancer macromolecule, K1.1.

Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 36 employees and 50 generic prescription drugs on the market in Canada. In parallel, Sunshine Biopharma is continuing its drug development R&D program. In addition to the K1.1 anticancer mRNA project, the Company is working on the development Adva-27a, a small molecule having the unique ability to destroy multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells, and uterine sarcoma cells. Clinical trials for pancreatic cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a COVID-19 treatment in collaboration with the University of Arizona. The project, currently in advanced stages of preclinical studies, is focused on the development of an inhibitors for SARS-CoV-2 PLpro protease. PLpro is unique to the SARS group of Coronaviruses and is responsible for suppressing the human immune system making this group of viruses more deadly.

For more information, please visit: Sunshine Biopharma Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Sunshine Biopharma (SBFM: NASDAQ) Agreement with a LNP Formulation Company first appeared on Financial Buzz .

For further details see:

“The Buzz” Show: Sunshine Biopharma (SBFM: NASDAQ) Agreement with a LNP Formulation Company
Stock Information

Company Name: Sunshine Biopharma Inc.
Stock Symbol: SBFM
Market: OTC
Website: sunshinebiopharma.com

Menu

SBFM SBFM Quote SBFM Short SBFM News SBFM Articles SBFM Message Board
Get SBFM Alerts

News, Short Squeeze, Breakout and More Instantly...